- Trials with a EudraCT protocol (16)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
16 result(s) found for: Clostridia.
Displaying page 1 of 1.
EudraCT Number: 2012-000531-88 | Sponsor Protocol Number: FID-EC-0001 | Start Date*: 2012-08-30 | |||||||||||
Sponsor Name:Astellas Pharma Europe Ltd. | |||||||||||||
Full Title: A Phase IIIb/IV Randomized, Controlled, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy of Fidaxomicin to Vancomycin in the Sustained Clinical Cure of Clostridium Difficile... | |||||||||||||
Medical condition: Adult patients with Clostridium difficile infection who are receiving immunosuppressive therapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Prematurely Ended) AT (Completed) IT (Prematurely Ended) FI (Prematurely Ended) GB (Completed) DE (Prematurely Ended) HU (Completed) GR (Completed) BE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020941-29 | Sponsor Protocol Number: AC-061A201 | Start Date*: 2010-11-03 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd | |||||||||||||
Full Title: A multi-center, double-blind, randomized, active reference, parallel group study to evaluate the efficacy, safety and tolerability of a 10-day twice daily oral administration of 3 doses of ACT-1798... | |||||||||||||
Medical condition: Clostridium difficile infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003004-24 | Sponsor Protocol Number: 2015-003004-24 | Start Date*: 2015-11-13 | |||||||||||
Sponsor Name:Aarhus University Hospital | |||||||||||||
Full Title: Faecal microbiota transplantation for relapsing Clostridium difficile infection | |||||||||||||
Medical condition: Relapsing Clostridium difficile infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004994-94 | Sponsor Protocol Number: 3415A-002 | Start Date*: 2011-12-21 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. difficile toxin B), and MK-... | |||||||||||||
Medical condition: Recurrence of Clostridium difficile infection (CDI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) ES (Completed) DE (Completed) CZ (Completed) FI (Completed) PL (Completed) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004590-90 | Sponsor Protocol Number: 3415A-001 | Start Date*: 2012-02-17 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium ... | |||||||||||||
Medical condition: recurrence of Clostridium difficile infection (CDI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) CZ (Completed) BE (Completed) DK (Completed) PT (Completed) AT (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002528-17 | Sponsor Protocol Number: AC-061A301 | Start Date*: 2014-03-14 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd | |||||||||||||
Full Title: A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD) | |||||||||||||
Medical condition: Clostridium difficile-associated diarrhea (CDAD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) ES (Completed) PL (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002508-15 | Sponsor Protocol Number: AC-061A302 | Start Date*: 2014-03-03 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd | |||||||||||||
Full Title: A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD) | |||||||||||||
Medical condition: Clostridium difficile-associated diarrhea (CDAD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BE (Completed) HU (Completed) SK (Completed) GR (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005483-25 | Sponsor Protocol Number: SMT19969/C003 | Start Date*: 2014-10-08 | |||||||||||
Sponsor Name:Summit (Oxford) Limited | |||||||||||||
Full Title: A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200 mg BID) for 10 days Compared with Fidaxomicin (200 mg BID) for 10 days f... | |||||||||||||
Medical condition: Clostridium difficile infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003934-22 | Sponsor Protocol Number: VLA84-201 | Start Date*: 2014-12-10 | |||||||||||
Sponsor Name:Valneva Austria GmbH | |||||||||||||
Full Title: DOSE-CONFIRMATION, IMMUNOGENICITY AND SAFETY STUDY OF THE CLOSTRIDIUM DIFFICILE VACCINE CANDIDATE VLA84 IN HEALTHY ADULTS AGED 50 YEARS AND OLDER. RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE II S... | |||||||||||||
Medical condition: Prevention against Clostridium difficile infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000947-26 | Sponsor Protocol Number: CLFF571X2201 | Start Date*: 2012-08-28 | |||||||||||
Sponsor Name:Novartis Farmacéutica S.A | |||||||||||||
Full Title: Multi-center, randomized, evaluator-blind, active-controlled, parallel-group design to determine safety, tolerability, and efficacy of multiple daily administration of LFF571 for 10 days in patien... | |||||||||||||
Medical condition: Clostridium difficile infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) PT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004924-14 | Sponsor Protocol Number: BSTEP | Start Date*: 2022-04-21 | |||||||||||||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||||||||||||
Full Title: New treatment strategy for patients with multiple recurrent Clostridioides difficile infection with bezlotoxumab as first option | |||||||||||||||||||||||
Medical condition: recurrent C. difficile infection | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004805-17 | Sponsor Protocol Number: AC-061A303 | Start Date*: 2017-07-12 | ||||||||||||||||||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd. | ||||||||||||||||||||||||||||
Full Title: A prospective, multicenter study to investigate the pharmacokinetics, safety, and efficacy of cadazolid versus vancomycin in pediatric subjects with Clostridium difficile-associated diarrhea. | ||||||||||||||||||||||||||||
Medical condition: Clostridium difficile-associated diarrhea (CDAD) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) HU (Completed) IT (Completed) ES (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-020484-20 | Sponsor Protocol Number: 20621-200 | Start Date*: 2011-07-05 | |||||||||||
Sponsor Name:ViroPharma Incorporated | |||||||||||||
Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF VP 20621 FOR PREVENTION OF RECURRENCE OF CLOSTRIDIUM DIFFICILE INFECTION (CDI) IN AD... | |||||||||||||
Medical condition: Clostridium difficile infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001641-27 | Sponsor Protocol Number: SMT19969/C004 | Start Date*: 2019-07-05 | |||||||||||
Sponsor Name:Summit (Oxford) Limited | |||||||||||||
Full Title: A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment ... | |||||||||||||
Medical condition: Clostridium difficile infection (CDI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GR (Prematurely Ended) BG (Completed) ES (Ongoing) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001642-10 | Sponsor Protocol Number: SMT19969/C005 | Start Date*: 2019-03-13 | |||||||||||
Sponsor Name:Summit (Oxford) Limited | |||||||||||||
Full Title: A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment ... | |||||||||||||
Medical condition: Clostridium difficile infection (CDI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LV (Completed) LT (Completed) BE (Prematurely Ended) DE (Completed) CZ (Completed) ES (Ongoing) FR (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004907-69 | Sponsor Protocol Number: H-030-011 | Start Date*: 2008-11-25 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Sanofi Pasteur Inc. | ||||||||||||||||||||||||||||||||||||||
Full Title: A Phase II randomized, placebo-controlled, double-blind, dose ranging study of a Clostridium difficile toxoid vaccine (ACAM-CDIFF) in subjects with Clostridium difficile-associated infection(CDI) | ||||||||||||||||||||||||||||||||||||||
Medical condition: Recurrence of Clostridium difficile Infection (CDI) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
